CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
Prioritising Alzheimer’s disease policy in Europe: Insights from oncology
However, current levels of policy development do not reflect the urgency for change, especially given the progress made in understanding the disease and new...